Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy | MicrobiomeTrials← Back to trialsNCT07103746
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-04-21Est. Completion: 2028-08
Enrollment target: 30 participants Locations- University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & Rheumatology, Birmingham, Alabama, United States
- Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States
- University of Chicago, Department of Medicine: Rheumatology, Chicago, Illinois, United States
- Johns Hopkins Hospital: Division of Rheumatology, Baltimore, Maryland, United States
- Mayo Clinic: Division of Rheumatology, Rochester, Minnesota, United States
- Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology, Great Neck, New York, United States
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania, United States
- University of Texas - Houston, Houston, Texas, United States
Other microbiome trials you might be interested in
DermatomyositisPolymyositisInclusion Body Myositis
This study will evaluate subjects with adult- and childhood-onset myositis to learn more about their cause and the immun…
Atlanta, United States
NMOSDNeuromyelitis Optica Spectrum Disorder
The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), an…
Beijing, ChinaEst. completion Sep 19, 2028
Phase 2
Recruiting
Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patient…
Boston, United StatesEst. completion Feb 5, 2025